Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected as new entrants including Boehringer Ingelheim, Amgen, Pfizer and Roche offer novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly)
A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists
Shi Q, Nong K, Vandvik PO et al (2023) Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Your body needs vitamin B12, but it cannot produce it
"We really need to think about how we can tackle these issues in a more holistic way."
US$ 28.85
US$ 20.03
US$ 27.23
US$ 25.66
US$ 25.39
US$ 26.37
US$ 27.78
US$ 21.36
